Rigel (RIGL) AI Stock Analysis

• Market Cap: $509.06M
• Dividend Yield: N/A
• Average Volume (3M): 530.80K
• Price to Earnings (P/E): 5.2
• Beta (1Y): 2.10
• Revenue Growth: 79.13%
• EPS Growth: 2798.12%
• Country: US
• Employees: 162
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.46
• Shares Outstanding: 17,937,340
• 10 Day Avg. Volume: 430,319
• 30 Day Avg. Volume: 530,797
• PEG Ratio: -0.10
• Price to Book (P/B): 89.93
• Price to Sales (P/S): 1.65
• P/FCF Ratio: 9.41
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $45.67
• Price Target Upside: 20.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 82 Outperform
• Price Target: $44.00 ▲(16.25% Upside)

Rigel's strong financial performance and positive earnings call are the most significant factors driving the high score. The stock's attractive valuation and bullish technical indicators further support its potential, though caution is advised due to the RSI nearing overbought levels.

Positive Factors

Revenue Growth

The significant revenue growth demonstrates Rigel's strong market position and successful product commercialization, indicating robust demand and effective sales strategies.

Pipeline Advancements

Advancements in Rigel's drug development pipeline, particularly in R289, suggest potential for future product approvals and long-term growth in the hematology and oncology sectors.

Cash Generation

Strong cash flow growth enhances Rigel's financial flexibility, supporting ongoing R&D investments and strategic initiatives, crucial for sustaining long-term operations.

Negative Factors

High Leverage

Elevated leverage could strain Rigel's financial stability, limiting its ability to invest in growth opportunities and increasing vulnerability to economic downturns.

Negative Return on Equity

Negative ROE indicates Rigel's challenges in generating returns from equity, potentially impacting investor confidence and long-term shareholder value.

Program Termination

The termination of the CNS program could reduce Rigel's diversification in its pipeline, impacting its strategic growth and innovation potential in the long term.

Rigel Business Overview & Revenue Model

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

How the Company Makes Money

Rigel Pharmaceuticals generates revenue through several key streams, primarily from the commercialization of its approved therapies. The company earns money by selling its marketed drugs, which include treatments for specific hematologic conditions. Additionally, Rigel may receive milestone payments and royalties from partnerships with larger pharmaceutical companies that involve co-development or licensing agreements for its drug candidates. Research and development collaborations also contribute to its revenue, allowing Rigel to leverage its technology and expertise while sharing costs and risks with partners. The success of its clinical trials and the subsequent approval of new therapies are critical factors influencing its earnings potential.

Rigel Financial Statement Overview

Summary

Rigel demonstrates strong revenue growth and profitability improvements, particularly in the latest TTM period. The income statement shows robust sales performance and high gross profit margins. However, the balance sheet reveals high leverage, posing financial risk, and the return on equity is negative. Cash flow generation is strong, but operational cash efficiency could improve.

Income Statement

Rigel's income statement shows strong revenue growth with a 31.93% increase in TTM, indicating robust sales performance. The gross profit margin remains high at 89.64%, reflecting efficient cost management. The net profit margin improved significantly to 18.31%, showcasing enhanced profitability. However, historical volatility in EBIT and EBITDA margins suggests potential operational challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 3.29 in TTM, indicating significant leverage, which could pose financial risk. Despite this, the company has improved its equity position over time. The return on equity is negative, suggesting inefficiencies in generating returns from shareholders' equity.

Cash Flow

Rigel's cash flow statement is strong, with an impressive 85.33% growth in free cash flow in TTM, indicating improved cash generation. The free cash flow to net income ratio is healthy at 1.00, showing effective conversion of profits into cash. However, the operating cash flow to net income ratio is moderate, suggesting room for improvement in operational cash efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	282.08M	179.28M	116.88M	120.24M	149.24M	108.62M
Gross Profit	262.62M	160.63M	109.77M	118.49M	148.15M	107.73M
EBITDA	122.63M	28.51M	-16.98M	-53.87M	-11.29M	-27.68M
Net Income	113.30M	17.48M	-25.09M	-58.57M	-17.91M	-29.74M
Balance Sheet
Total Assets	242.53M	163.98M	117.22M	134.28M	167.33M	110.38M
Cash, Cash Equivalents and Short-Term Investments	137.14M	77.32M	56.93M	58.21M	124.97M	57.33M
Total Debt	60.88M	59.97M	60.58M	41.55M	30.57M	39.09M
Total Liabilities	124.92M	160.69M	145.87M	147.90M	136.95M	76.35M
Stockholders Equity	117.61M	3.29M	-28.64M	-13.62M	30.37M	34.03M
Cash Flow
Free Cash Flow	68.14M	31.43M	-20.74M	-74.21M	5.25M	-53.45M
Operating Cash Flow	68.18M	31.47M	-5.74M	-73.76M	5.88M	-52.19M
Investing Cash Flow	-77.92M	4.13M	-4.30M	72.78M	-80.04M	47.47M
Financing Cash Flow	6.64M	-11.64M	18.37M	6.55M	62.67M	12.57M

Rigel Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 37.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Positive. The current price of 37.85 is above the 20-day moving average (MA) of 29.67, above the 50-day MA of 32.43, and above the 200-day MA of 24.30, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 69.06 is Neutral, neither overbought nor oversold. The STOCH value of 43.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RIGL.

Rigel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	82 Outperform	$509.06M	5.24	220.06%	―	79.13%	2798.12%
LXRX	57 Neutral	$483.32M	-3.99	-65.30%	―	1504.83%	56.81%
RGNX	55 Neutral	$583.94M	―	-62.49%	―	74.95%	34.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VSTM	44 Neutral	$528.20M	―	-2888.70%	―	33.79%	-26.37%
BCYC	41 Neutral	$476.14M	―	-34.63%	―	-23.43%	-9.84%
OPT	39 Underperform	$477.76M	-3.01	―	―	-80.09%	60.14%

Rigel Corporate Events

Rigel Pharmaceuticals Reports Record Q3 Revenue and Growth

Rigel Pharmaceuticals’ recent earnings call reflected a robust financial performance, marked by substantial revenue growth and promising advancements in their drug development pipeline. Despite a setback with the termination of a CNS program by Eli Lilly, the overall sentiment was optimistic, focusing on the company’s growth and future expansion opportunities.

Rigel Pharmaceuticals Reports Strong Q3 2025 Results

Rigel Pharmaceuticals, Inc., a biotechnology company based in South San Francisco, focuses on developing therapies for hematologic disorders and cancer. The company is known for its innovative approach in the biotechnology sector, particularly in the treatment of immune thrombocytopenia and acute myeloid leukemia.

Eli Lilly and Rigel’s Promising Study on Rheumatoid Arthritis Treatment

Eli Lilly and Company, in collaboration with Rigel Pharmaceuticals, is conducting an adaptive Phase 2a/2b study titled ‘An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.’ The study aims to evaluate the efficacy and safety of LY3871801 in treating adults with active moderate-to-severe rheumatoid arthritis, a condition that significantly impacts quality of life.

Rigel Pharmaceuticals’ Earnings Call Highlights Robust Growth

Rigel Pharmaceuticals’ recent earnings call painted a picture of robust growth and optimism. The company reported significant revenue increases and strong commercial performance across its product portfolio. With raised revenue guidance for 2025, Rigel demonstrates confidence in its continued growth trajectory. The call highlighted financial discipline leading to increased profitability, alongside a promising development pipeline. A minor lowlight involved a change in patient response status in a clinical study.

Rigel Pharmaceuticals Reports Strong Q2 2025 Results

Rigel Pharmaceuticals, Inc. is a biotechnology company based in South San Francisco, specializing in the discovery, development, and commercialization of innovative therapies for hematologic disorders and cancer. The company is known for its focus on hematology and oncology, with a pipeline of products aimed at addressing unmet medical needs in these areas.